Does the HHS peptide draft cover blends and peptide stacks?

API means active pharmaceutical ingredient. The HHS draft says the compounded product contains “only a single Active Pharmaceutical Ingredient (API) listed in Appendix A,” and its explanation calls for single-API products. That is a meaningful boundary for interpreting a headline about six substances.

Listing BPC-157 and TB-500 separately does not establish that a vial containing both is within the described policy. The Federal Register notice also calls this a draft, with publication scheduled October 30, 2026. On October 28, neither a blend nor a single-ingredient product should be described as newly FDA-approved through this document.

A blend places multiple active ingredients in one preparation. “Stack” is informal marketing language that can refer to using several separate products. The draft’s single-API condition directly addresses the preparation; it does not provide a clinical protocol for taking several products together.

Separate containers do not establish that a combination is appropriate for a patient. Ask the clinician to identify each ingredient, why each is proposed, what evidence supports concurrent use, and how risks would be monitored. Do not turn a policy limitation on one vial into an assumption that any multi-product regimen has been evaluated or endorsed.

The appendices should be read together. Appendix A supplies the six familiar names, while Appendix B narrows the identities. Examples include BPC-157 acetate and Semax free base. TB-500 acetate in this policy refers to the acetylated seven-amino-acid fragment, not full-length thymosin beta-4.

A similar name or shared biological story is not enough to establish coverage. Research on a parent protein, analogue, or differently formulated product should also be identified accurately. Ask for the exact chemical identity rather than accepting “the same peptide family” as a substitute for the policy’s specified substance.

No. The draft specifies KPV acetate for topical and oral dosage forms and Semax free base for intranasal use. It does not establish injectable KPV or injectable Semax within those provisions. Other listed substances have their own route limits, and epitalon’s injectable wording includes intermittent courses without supplying a numerical treatment schedule.

For oral forms, the draft separately calls for documentation of adequate human oral bioavailability for the specific formulation. A route appearing in an appendix does not erase that additional condition. Readers should ask how the exact dosage form fits every relevant provision instead of reasoning from an ingredient name alone.

Ask whether the seller is discussing one preparation, multiple prescriptions, or laboratory material. Request the current source supporting the regulatory claim and the separate human evidence supporting the proposed use. These are different kinds of evidence and should not be combined into a single statement that a blend is “cleared.”

The FDA compounding questions and answers explains the distinction between compounded and FDA-approved drugs. The policy does not replace that distinction with a new approval category. If you are already taking several substances, share the complete list with your clinician and avoid changing the regimen based solely on this announcement. Our doctor-discussion guide can help organize that conversation.